Was betrifft es? Warum ist das wichtig?

Drug and Device Accountability (DDA) refers to the study documentation of an Investigational Therpeutic Product (IP), such as an IMP or IMD (e.g. shipment, storage, preparation, use, destruction).

 

For a SP-INV, DDA accountability:

 

For a Site-INV, DDA accountability:

  • Starts once the IP is delivered to the study site
  • Continues with ongoing IP tracking during study conduct. Such as the IP being:
    • Removed from storage site, or delivered by a hospital pharmacy
    • Distributed to study participants
    • Returned by participants to the study site
  • Ends with used or un-used IP being returned to the SP-INV or destroyed at the study site

 

DDA-logs are subject to reviews during study monitoring visits, and potential RA inspections (e.g. Swissmedic).

Mehr

IP oversight also includes a:

  • Collaboration with IP providers (e.g. MAH, pharmacy)
  • SP-INV specifications regarding IP storage requirements (e.g. required storage temperature, humidity, light), including faultless IP storage, based on IP instruction for use
  • Restricted access to IP-storage sites (e.g. study site delegation-log). This ensures that the DDA-log remains current and correct, and IP is protected against accidental loss or damage
  • Faultless IP dispensing to study participants (e.g. IP preparation, IP labelling information, IP dosage escalations, removal of damaged IP, faultless execution)
  • Faultless ongoing IP documentation. This includes the proof that any placebo or comparator was handled and administered according to the study protocol

Was muss ich befolgen?

As a SP-INV, implement DDA procedures and document IP:

  • Ordered and received by licensed providers (e.g. pharmacy, manufacturer)
  • Distributed to study sites
  • Used during study conduct (e.g. based on the monitoring of IP-use by study participants – used/not used)
  • Expiration and any stability testing during study conduct
  • Returned from participating study sites, including its destruction

 

As a Site-INV, maintain ongoing oversight of IP-Inventory and use. Document ongoing:

 

As a Site-INV, manage IP storage, such as to:

  • Ensure ongoing optimal storage conditions
  • Check for expired IPs and if applicable:
    • Send expired IPs for stability testing
    • Relabel IPs (i.e. based on SP-INV SOPs) with the SP-INV approved updated expiration date
  • Return unused or expired IPs to the SP-INV, or destroy IPs based on SP-INV SOPs

Mehr

As a Site-INV, during study conduct:

  • Do not discard empty IP blisters, vials, or bottles before the study monitor was able to document its use. This information enables the SP-INV to track IP-use at the study site during study conduct (e.g. use is tracked based on which study participant received and used which IP lot/serial number)
  • In the event IPs are destroyed at the study site, provide the SP-INV with a certificate of destruction

Wo kann ich Hilfe anfordern?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guidelines

  • 2.10 Investigational Product Management (Investigator)
  • 3.15 Investigational Product(s)
  • 3.15.3 Supplying and handling investigational products(s)
  • C.3 Essentiality of Trial Records - Accountability

ISO 14155:2020 Medical devices (access liable to cost) - see in particular section

  • 7.9 Investigational device accountability
Abkürzungen
  • CTU – Clinical Trials Unit
  • DDA – Drug and Device Accountability
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • IMP – Investigational Site File
  • IMP/MD – Investigational Site File / Medical Device
  • IP - Investigational Product
  • ISO – International Organization for Standardization
  • MAH – Manufacturing Authorisation Holder
  • MD – Medical Device
  • RA – Regulatory Authorities
  • SOP – Standard Operating Procedures
  • Site-INV – Site Investigator
  • SP-INV – Sponsor-Investigator
Conduct ↦ Management ↦ Responsibility and Oversight ↦ Drug and Device Accountability
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Management ↦ Responsibility and Oversight ↦ Drug and Device Accountability